Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
This significant milestone enhances our global regulatory standing
This approval authorizes the company to export Ibuprofen to the Chinese markets
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Strengthening capabilities in Peptide Therapeutics and CDMO services
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Subscribe To Our Newsletter & Stay Updated